Verve Therapeutics Inc (VERV)

Currency in USD
11.13
+0.03(+0.27%)
Real-time Data·
Showing Verve Therapeutics historical data. For real-time data please try another search
Fair Value
Day's Range
11.1011.25
52 wk Range
2.8611.41
Key Statistics
Prev. Close
11.13
Open
11.14
Day's Range
11.1-11.25
52 wk Range
2.86-11.41
Volume
10.31M
Average Volume (3m)
5M
1-Year Change
58.55%
Book Value / Share
5.33
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VERV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.50
Upside
+21.29%
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Verve Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Verve Therapeutics Inc Company Profile

Verve Therapeutics, Inc., a clinical-stage company, develops gene editing medicines for patients to treat cardiovascular disease in the United States. The company’s product candidates include VERVE-101, which is being evaluated in the Heart-1 trial, an open-label Phase 1b clinical trial, as well as changes in blood PCSK9 protein and LDL-C levels in patients living with heterozygous familial hypercholesterolemia (HeFH); VERVE-102 that is being evaluated in the Heart-2 trial, an open-label Phase 1b clinical trial in adult patients with HeFH, and/or premature coronary artery diseases; VERVE-201, which targets ANGPTL3 and permanently turn off the ANGPTL3 gene in the liver; and VERVE-301, a development candidate that uses a novel in vivo gene editing approach to permanently turn off the LPA gene in the liver to reduce blood Lp(a) levels. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; a license agreement to lipid technology with Novartis Pharma AG; Eli Lilly and Company; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is based in Boston, Massachusetts. As of July 25, 2025, Verve Therapeutics, Inc. operates as a subsidiary of Ridgeway Acquisition Corporation.

Verve Therapeutics Inc SWOT Analysis


Gene Editing Pionee
Verve Therapeutics leads cardiovascular treatment innovation with promising PCSK9 program results, showcasing potential for long-lasting genetic solutions
Trial Triumph
Phase 1b Heart-2 trial data reveals significant PCSK9 and LDL-C reductions, paving the way for advanced studies and potential market disruption
Strategic Partnerships
Collaboration with Eli Lilly bolsters Verve's position, offering financial support and expertise to accelerate development and commercialization efforts
Market Valuation
Analyst targets range from $15 to $39 per share, reflecting optimism amid challenges. Strong liquidity and revenue growth offset cash burn concerns
Read full SWOT analysis

Compare VERV to Peers and Sector

Metrics to compare
VERV
Peers
Sector
Relationship
P/E Ratio
−5.5x0.0x−0.5x
PEG Ratio
−0.210.000.00
Price/Book
2.1x0.0x2.6x
Price / LTM Sales
16.7x0.0x3.3x
Upside (Analyst Target)
19.0%0.0%42.4%
Fair Value Upside
Unlock0.0%7.2%Unlock

Analyst Ratings

1 Buy
2 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 13.50
(+21.29% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.35 / -0.65
Revenue / Forecast
32.98M / 7.88M
EPS Revisions
Last 90 days

VERV Income Statement

People Also Watch

266.39
AVAV
-0.53%
115.85
CRWV
+12.59%
35.45
BMNR
+3.04%
14.22
OSCR
+1.54%
78.97
OKLO
+4.42%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.